Immuno-oncology Development Trends and Opportunities

NEW YORK/PRNewswire/ -- Immuno-oncology Development Trends and Opportunities

Summary

Read the full report: https://www.reportlinker.com/p05644051 

"Immuno-oncology Development Trends and Opportunities", report provides an overview of current clinical development trends for Immuno-Oncology (IO) within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including a history of recent approvals, indications currently being explored for Immuno-Oncology (IO) agents of all modalities, targets being selected for Immuno-Oncology (IO) therapies, and combination strategies being investigated for approved Immuno-Oncology (IO) agents.

In addition, the report provides disease overviews, epidemiology, current recommended treatment regimens and Immuno-Oncology (IO) approvals, and Immuno-Oncology (IO) clinical trial trends for 17 indications identified on the basis of representing the largest commercial opportunities for Immuno-Oncology (IO) agents. Clinical trial trends analyze ongoing trials by sponsor type and modality, as well as ongoing combination trials for approved Immuno-Oncology (IO) therapies.

Immuno-Oncology (IO) is the treatment of cancer with therapies that stimulate or suppress the body's own immune system. Several distinct modalities of IO therapy exist, including bispecific T-cell engaging monoclonal antibodies, cellular immunotherapy and adoptive cellular therapy, cancer vaccines, checkpoint modulating monoclonal antibodies, and oncolytic viruses.

Scope
This report combines primary research from a cross-specialty panel of oncology experts with in-house analyst expertise to provide an assessment of the development landscape.

Components of the slide deck include primary and secondary research -
- Quotes from 13 US-, 5EU-, and Japan-based key opinion leaders
- Summary of IO product definitions and classifications
- Overview of development opportunities for IO agents across indications, including emerging indications and clinical targets, and novel combination strategies
- Outline of 17 key indications for IO agents, including current EU and US guideline recommendations, IO's current place in the treatment algorithm, and a review of ongoing clinical trials
- Call-outs of key information and details
- Insight from GlobalData's specialist oncology analysts.

Reasons to buy
- Develop business strategies by understanding the trends shaping and driving IO in the 8MM.
- Drive revenues by understanding the key trends, innovative combination strategies and indications likely to impact the IO market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Organize your sales and marketing efforts by understanding IO combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Develop strategies by understanding expert perceptions of unmet needs in key indications in oncology, and the potential for IO agents to meet those needs.

Read the full report: https://www.reportlinker.com/p05644051 

Contact Clare: clare@reportlinker.com 
US: (339)-368-6001 
Intl: +1 339-368-6001

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Q: